Table 2.
Population parameter estimates of the immune reconstitution model
| Parameter | Estimate (RSE%) | Confidence intervals [5th – 95th] | |
|---|---|---|---|
| Pharmacodynamic parameters | CIRCEQ (109/L) | 0.79 (18.91) | [0.52–0.81] |
| IIV CIRCEQ (109/L) (CV%) | 75.90 (26.17) | [73.48–90.5] | |
| MTT (days) | 8.02 (12.04) | [6.91–10.63] | |
| IIV MTT (CV%) | 35.41 (36.95) | [35.35–45.82] | |
| GAMMA | 0.10 (13.93) | [0.07–0.11] | |
| IIV GAMMA (CV%) | 77.10 (11.23) | [72.80–80.62] | |
| KKILL BUSULFAN (L/μmol) | 0.70 (13.45) | [0.45–0.71] | |
| IIV KKILL (CV%) | 54.91 (46.72) | [44.71–55.71] | |
| EMAX TREOSULFAN | 1.20 (10.71) | [1.13–1.52] | |
| C50 TREOSULFAN (mg/L) | 1.40·10−4 (12.23) | [1.1·10−4 – 1.5·10−4] | |
| IIV C50 (CV%) | 44.73 (39.81) | [44.68–47.83] | |
| Transplant effect: Kprol and gamma | 1.05 (2.77) | [1.01–1.08] | |
| Transplant effect: Transit | 1.03 (11.41) | [0.88–1.15] | |
| Transplant effect: Transit + Alem | 1.98 (12.46) | [1.63–2.32] | |
| Latency time transplant (days) | 9.07 (25.13) | [8.90–17.20] | |
| IIV latency time transplant (CV%) | 99.5 (13.43) | [78.68–99.70] | |
| IIV bioavailability transplant (CV%) | 114 (26.01) | [113.13–134.31] | |
| Residual error[log (109/L)] | 0.60 (5.78) | [0.59–0.71] |
CIRCEQ; absolute neutrophil count at steady state; IIV; interindividual variability; MTT; mean transit time; KKILL; killing constant; Kprol; proliferation constant; Alem; coadministration of alemtuzumab; CV; coefficient of variation.